Skip to main content

Table 3 Results of the cost-utility analysis

From: Cost-utility analysis of percutaneous mitral valve repair in inoperable patients with functional mitral regurgitation in German settings

Treatment arm Cost, € Incremental cost, € LYG Incremental LYG QALY gained Incremental QALY gained ICER, €/QALY
Optimal medical treatment 18,944   4.46   2.91   
Percutaneous mitral valve repair 36,785 17,841 5.87 1.41 4.06 1.15 15,533
  1. ICER – incremental cost-effectiveness ratio; LYG – life years gained; QALY – quality-adjusted life years